- Bacillus Calmette-Guérin (BCG)
- Transurethral Resection of Bladder Tumor (TURBT)
- Urologic Oncology
- Pathology
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Carcinoma in Situ (CIS)
- Muscle Invasive Bladder Cancer (MIBC)
- Bladder Cancer
Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes.
This podcast is supported by an educational grant from Johnson & Johnson.